Period:
Draw Mode:
| Volume | 18,640 |
|
|||||
| News | - | ||||||
| Day High | 1.45 | Low High |
|||||
| Day Low | 1.38 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rezolute Inc | RZLT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 2.16% | 1.42 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.45 | 1.38 | 1.45 | 1.42 | 1.39 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 133 | 18,640 | $ 1.41 | $ 26,218 | - | 1.31 - 3.19 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 100 | $ 1.42 | USD |
Rezolute Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 52.3M | 36.83M | - | 0 | -41.06M | -1.11 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rezolute News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RZLT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.57 | 1.57 | 1.37 | 1.47 | 34,426 | -0.15 | -9.55% |
| 1 Month | 1.43 | 1.65 | 1.31 | 1.47 | 29,620 | -0.01 | -0.7% |
| 3 Months | 1.81 | 2.38 | 1.31 | 1.67 | 33,251 | -0.39 | -21.55% |
| 6 Months | 2.14 | 2.4055 | 1.31 | 1.86 | 32,564 | -0.72 | -33.64% |
| 1 Year | 2.93 | 3.19 | 1.31 | 1.91 | 45,750 | -1.51 | -51.54% |
| 3 Years | 20.14 | 21.20 | 1.31 | 4.58 | 58,088 | -18.72 | -92.95% |
| 5 Years | 20.14 | 21.20 | 1.31 | 4.58 | 58,088 | -18.72 | -92.95% |
Rezolute Description
| Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. |